

OUT 04 2005
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

| | | |
|---------------------------------------|----------------------|--------------------|
| (Multiple sheets used when necessary) | Application No. | 10/660,357 |
| SHEET 1 OF 2 | Filing Date | September 10, 2003 |
| | First Named Inventor | Menashe Bar-Eli |
| | Art Unit | 1642 |
| | Examiner | David J. Blanchard |
| | Attorney Docket No. | ABGENIX.030C1 |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Document Number Number - Kind Code (if known) Example: 1,234,567 B1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|-------------------|----------|---|--------------------------------|-------------------------------|--|
| DB | 1 | 5,466,468 | 11/14/1995 | Schneider et al. | |
| | 2 | 5,800,820 | 09/01/1998 | Maione | |
| | 3 | 6,024,956 | 02/12/2000 | Matsushima et al. | |
| | 4 | 6,133,426 | 10/17/2000 | Gonzalez et al. | |
| | 5 | 6,150,584 | 11/21/2000 | Kucherlapati et al. | |
| | 6 | 6,229,048 | 05/08/2001 | Mazur et al. | |
| DB | 7 | 6,342,221 | 01/29/2002 | Thorpe et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ¹ |
|-------------------|----------|--|--------------------------------|-------------------------------|--|----------------|
| DB | 8 | WO 98/24893 A2 | 06/11/1998 | ABGENIX, INC. | | |
| DB | 9 | WO 03/057006 A2 | 07/17/2003 | ABGENIX, INC. | | |
| DB | 10 | EP 0 710 719 A | 05/18/1996 | ABGENIX, INC. | | |


NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
|-------------------|----------|---|----------------|
| DB | 11 | Arenberg et al. "Inhibition of Interleukin-8 Reduces Tumorigenesis of Human Non-Small Cell Lung Cancer in SCID Mice." <i>J. Clin. Invest.</i> , 97(12):2792-2802 (1996). | |
| | 12 | Davis, et al. "Transgenic mice as a source of fully human antibodies for the treatment of cancer." <i>Cancer and Metastasis Reviews</i> , 18:421-425 (1999). | |
| | 13 | Green et al. "Interleukin-8 (IL-8), Melanoma Growth-stimulatory Activity, and Neutrophil-activating Peptide Selectivity Mediate Priming of the Neutrophil NADPH Oxidase through the Type A or Type B IL-8 Receptor." <i>The Journal of Biological Chemistry</i> , 271(41):25400-25405 (1996). | |
| | 14 | Lehmann et al. "MUC18 a marker of tumor progression in human melanoma shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily." <i>Proceedings of the National Academy of Sciences USA</i> , 86:9891-9895 (1989). | |
| | 15 | Luca et al. "Expression of Interleukin-8 by Human Melanoma Cells Up-Regulates MMP-2 Activity Increases Tumor Growth and Metastasis." <i>American Journal of Pathology</i> , 4:1105-1113 (1997). | |
| | 16 | Mendez et al. "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice." <i>Nature Genetics</i> , 15(2):146-156 (1997). | |
| DB | 17 | Michi et al. "Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells." <i>Oral Oncology</i> , 36:81-88 (2000). | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 11/28/05 |
|--------------------|--|-----------------|----------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.



| | |
|----------------------|--------------------|
| Application No. | 10/660,357 |
| Filing Date | September 10, 2003 |
| First Named Inventor | Menashe Bar-Eli |
| Art Unit | 1642 |
| Examiner | David J. Blanchard |
| Attorney Docket No. | ABGENIX.030CI |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
| DB | 18 | Rofstad et al. "Vascular Endothelial Growth Factor, Interleukin-8, Platelet-derived Endothelial Cell Growth Factor, and Basic Fibroblast Growth Factor Promote Angiogenesis and Metastasis in Human Melanoma Xenografts." <i>Cancer Research</i> , 60:4932-4938 (2000). | |
| DB | 19 | Scott et al. "Atracurium: Clinical strategies for preventing histamine release and attenuating the haemodynamic response." <i>Br. J. Anaesth.</i> , 57:550-553 (1985). | |
| DB | 20 | Shih et al. "A new MEL-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue." <i>Modem Pathology</i> , 11(11):1098-1106 (1998). | |
| DB | 21 | Shih, Le-Ming. "The role of CD146 (MEL-CAM) in biology and pathology." <i>Journal of Pathology</i> , 189(1):4-11 (1999). | |
| DB | 22 | Singh et al. "Ultraviolet B Irradiation Promotes Tumorigenic and Metastatic Properties in Primary Cutaneous Melanoma via Induction of Interleukin 8 ¹ ." <i>J. Cancer Research</i> , 55:3669-3674 (1995). | |
| DB | 23 | Yang et al. "Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy." <i>Critical Reviews in Oncology-Hematology</i> , 38(1):17-23 (2001). | |

1965353 : 093005/CAP

| | |
|--|---------------------------------|
| Examiner Signature <i>David J. Blanchard</i> | Date Considered <i>11/28/05</i> |
|--|---------------------------------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.